MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Suletud

SektorTervishoid

544.84 2.82

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

534.3

Max

546.33

Põhinäitajad
By Trading Economics
Sissetulek	56M -59M
Müük	34M 321M
Kasumimarginaal	-18.243
Töötajad	915
EBITDA	56M -50M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+28.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1B 12B
Eelmine avamishind	542.02
Eelmine sulgemishind	544.84

Uudiste sentiment

By Acuity

38%

62%

110 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

263.2 / 277.1 Toetus ja vastupanu

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. apr 2026, 04:27 UTC

Uudisväärsed sündmused

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 18:30 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. apr 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. apr 2026, 16:50 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 16:12 UTC

Tulu

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

3. apr 2026, 15:20 UTC

Uudisväärsed sündmused

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. apr 2026, 15:08 UTC

Omandamised, ülevõtmised, äriostud

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. apr 2026, 14:11 UTC

Market Talk

Uudisväärsed sündmused

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. apr 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. apr 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. apr 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. apr 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. apr 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

28.89% tõus

12 kuu keskmine prognoos

Keskmine 704.88 USD 28.89%

Kõrge 964 USD

Madal 529 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Madrigal Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

110 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.